Downing Sue, Chien May B, Kass Philip H, Moore Peter E, London Cheryl A
Veterinary Cancer Referral Group, 1044 South Robertson Blvd, Los Angeles, CA 90035, USA.
Am J Vet Res. 2002 Dec;63(12):1718-23. doi: 10.2460/ajvr.2002.63.1718.
To determine the prevalence of activating internal tandem duplications (ITDs) in exons 11 and 12 of c-kit in mast cell tumors (MCTs) of dogs and to correlate these mutations with prognosis.
157 formalin-fixed, paraffin-embedded MCTs from dogs in the pathology database of the Veterinary Medical Teaching Hospital at the University of California, Davis.
Genomic DNA was isolated from tumor specimens and a polymerase chain reaction procedure was performed to determine whether there were ITDs in exons 11 and 12.
We identified ITDs in 1 of 12 (8%) grade-I, 42 of 119 (35%) grade-lI, and 9 of 26 (35%) grade-ll tumors (overall prevalence, 52 of 157 [33%]). Logistic regression analysis revealed that the odds of grade-II and -III tumors possessing an ITD were approximately 5 times greater than that for grade-I tumors, although these odds did not differ significantly. Although MCTs possessing an ITD were twice as likely to recur after excision and twice as likely to result in metastasis as those without an ITD, these values also did not differ significantly.
These results provide evidence that ITDs in c-kit occur frequently in MCTs of dogs. The high prevalence of c-kit activating mutations in MCTs of dogs combined with the relative abundance of mast cell disease in dogs provide an ideal naturally developing tumor in which to test the safety and efficacy of novel small-molecule kinase inhibitors such as imatinib mesylate.
确定犬肥大细胞瘤(MCTs)中c-kit基因第11和12外显子激活型内部串联重复(ITD)的发生率,并将这些突变与预后相关联。
来自加利福尼亚大学戴维斯分校兽医学院教学医院病理数据库中157例经福尔马林固定、石蜡包埋的犬MCTs。
从肿瘤标本中分离基因组DNA,并进行聚合酶链反应以确定第11和12外显子中是否存在ITD。
我们在12例I级肿瘤中的1例(8%)、119例II级肿瘤中的42例(35%)和26例III级肿瘤中的9例(35%)中鉴定出ITD(总体发生率,157例中的52例[33%])。逻辑回归分析显示,II级和III级肿瘤存在ITD的几率比I级肿瘤高约5倍,尽管这些几率差异不显著。尽管存在ITD的MCTs切除后复发的可能性是无ITD的MCTs的两倍,发生转移的可能性也是其两倍,但这些数值差异也不显著。
这些结果证明c-kit基因中的ITD在犬MCTs中频繁出现。犬MCTs中c-kit激活突变的高发生率以及犬肥大细胞疾病的相对高发性提供了一个理想的自然发生肿瘤,可用于测试新型小分子激酶抑制剂如甲磺酸伊马替尼的安全性和有效性。